AbbVie and Galderma dominate aesthetic medicine AI citations, study finds
AbbVie and Galderma took 80% of aesthetic-medicine AI citations, leaving 11,500 med spas fighting for just 5% of visibility.
AI search is turning aesthetic medicine into a winner-take-most market, and AbbVie and Galderma are sitting on the best seats. A June 23 5W visibility index found the two companies controlled 80% of AI citation share across ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews. The top 25 brands together captured 95% of all citation share, leaving 11,500 independent med spas chasing the remaining 5% in a U.S. category sized at roughly $25 billion.
The breakdown is stark. AbbVie and its Allergan aesthetic brands held 47% of citation share, Galderma held 33%, and Merz Aesthetics plus Revance split the remaining 20%. That is not a normal SEO story anymore. It is a patient-discovery problem, because the answer engines are now deciding which brands and providers get considered before a consumer ever clicks through to a website.
What the index shows is that AI systems are rewarding the same signals that already matter in a harder, more concentrated way: clear entity identity, structured treatment information, broad third-party references and enough authority that a model feels safe naming the brand. If a med spa’s name, specialty, service area or clinical legitimacy is fuzzy, it can disappear from the answer entirely. Larger chains should not confuse traditional market share with citation share either. Being well known in paid media or local search does not guarantee a place in the answer layer.
The category backdrop explains why the fight is getting sharper. The American Society of Plastic Surgeons said minimally invasive cosmetic procedures grew 7% in 2023, with neuromodulator injections topping 9 million and hyaluronic acid fillers above 5 million treatments. 5W’s earlier April 27 medical aesthetics visibility index already pointed in the same direction, ranking the top 25 brands across ChatGPT, Claude, Perplexity and Google AI Overviews in a $22 billion global market and highlighting names like Botox, Juvéderm, CoolSculpting, SkinCeuticals and Morpheus8 as AI-answer regulars.
AbbVie and Galderma are not landing on top by accident. AbbVie’s 2025 annual report describes leadership positions in aesthetics, and its portfolio includes facial injectables, plastics and regenerative medicine, body contouring and skincare products. Galderma’s 2025 annual report says the company advanced its injectable-aesthetics portfolio with regulatory progress on Relfydess and new indications for Restylane and Sculptra. That breadth of brands, plus the clinical-data and education footprint that comes with it, likely helps explain why the two companies are overrepresented in AI-generated answers. The lesson for smaller brands is blunt: build tighter entity signals, publish treatment pages that are specific enough for machines to trust, and monitor how AI systems describe the business before discovery gets locked up by the same handful of names.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
